AssetMark Inc’s Kiniksa Pharmaceuticals KNSA Stock Holding History

AssetMark Inc’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320	Hold	5	–	–	﹤0.01%	3365
2026 Q1	$241	Hold	5	–	–	﹤0.01%	3302
2025 Q4	$206	Hold	5	–	–	﹤0.01%	3250
2025 Q3	$194	Buy	+5	New	+$162	﹤0.01%	3068

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

AssetMark Inc's KNSA Position: Q2 2026 in Review

AssetMark Inc held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 5 shares worth $320. The position accounts for ﹤0.01% of the portfolio, ranked #3365.

AssetMark Inc first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

AssetMark Inc held 5 shares of Kiniksa Pharmaceuticals worth $320 as of Q2 2026.
AssetMark Inc left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3365 holding.
AssetMark Inc first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.